Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lenvatinib in Anaplastic Thyroid Cancer
NCT02657369Phase 2Terminated
- Sponsor
- Eisai Co., Ltd.
- Start
- Jul 2016
- Primary completion
- Sep 2018
- Modality
- Small Molecules
- Countries
- 5
01
Overview
A Phase 2 trial of lenvatinib in anaplastic thyroid cancer (ATC), sponsored by Eisai Co., Ltd.. Started Jul 2016; status: terminated.
02
Drugs
lenvatinib
03
Conditions
anaplastic thyroid cancer (ATC)
Beyond the preview
Go deeper on NCT02657369.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02657369.